JOHNSON & JOHNSON
13F Reported Value
ⓘ$798.7M
Holdings
15
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
JOHNSON & JOHNSON disclosed 15 positions worth $798.7M in its Form 13F-HR for Q2 2026, led by $PTGX (Protagonist Therapeutics, Inc) at 37.6% of the equity portfolio, followed by $NBTX and $MGTX. During the quarter the fund opened 1 new position and exited 2 — including a new stake in $CBRS and a full exit from $RLYB. The portfolio is most concentrated in Healthcare (98.5% of disclosed assets). All figures are sourced directly from JOHNSON & JOHNSON’s Form 13F-HR filing with the SEC under CIK 200406.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 59.4#932
Quality
$300.2M2,449,183 sh - —
Quality
$212.0M5,623,816 sh - —
Quality
$89.7M6,641,064 sh - —
Quality
$74.4M1,784,517 sh - —
Quality
$32.4M1,979,173 sh - 47.8
Quality
$23.5M814,586 sh - 28.1
Quality
$20.7M4,024,861 sh - 11.6
Quality
$12.0M748,062 sh - —
Quality
$11.8M53,586 sh - 9.2
Quality
$9.1M3,379,064 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Protagonist Therapeutics, Inc$PTGX | 59.4#932 | $300.2M | 2,449,183 |
 Nanobiotix S.A.$NBTX | — | $212.0M | 5,623,816 |
 MeiraGTx Holdings plc$MGTX | — | $89.7M | 6,641,064 |
 Rapport Therapeutics, Inc.$RAPP | — | $74.4M | 1,784,517 |
 Contineum Therapeutics, Inc.$CTNM | — | $32.4M | 1,979,173 |
 Legend Biotech Corp$LEGN | 47.8 | $23.5M | 814,586 |
 CVRx, Inc.$CVRX | 28.1 | $20.7M | 4,024,861 |
 Xencor Inc$XNCR | 11.6 | $12.0M | 748,062 |
 Cerebras Systems Inc.$CBRS | — | $11.8M | 53,586 |
 FATE THERAPEUTICS INC$FATE | 9.2 | $9.1M | 3,379,064 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of JOHNSON & JOHNSON's 15 positions.
Showing top 10 of 15 holdings.
Sector Allocation
Healthcare
$786.6M
Technology
$12.1M
Full Holdings — JOHNSON & JOHNSON (Q2 2026)
All 15 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PTGX | Protagonist Therapeutics, Inc | $300.2M | 37.6% | +0% | 59.4 |
| 2 | $NBTX | Nanobiotix S.A. | $212.0M | 26.6% | +0% | — |
| 3 | $MGTX | MeiraGTx Holdings plc | $89.7M | 11.2% | +0% | — |
| 4 | $RAPP | Rapport Therapeutics, Inc. | $74.4M | 9.3% | +0% | — |
| 5 | $CTNM | Contineum Therapeutics, Inc. | $32.4M | 4.1% | +0% | — |
| 6 | $LEGN | Legend Biotech Corp | $23.5M | 3.0% | +0% | 47.8 |
| 7 | $CVRX | CVRx, Inc. | $20.7M | 2.6% | +0% | 28.1 |
| 8 | $XNCR | Xencor Inc | $12.0M | 1.5% | +0% | 11.6 |
| 9 | $CBRS | Cerebras Systems Inc. | $11.8M | 1.5% | NEW | — |
| 10 | $FATE | FATE THERAPEUTICS INC | $9.1M | 1.1% | +0% | 9.2 |
| 11 |  $PRCT | PROCEPT BioRobotics Corp | $8.1M | 1.0% | +0% | 33.3 |
| 12 |  $NMRA | Neumora Therapeutics, Inc. | $3.1M | 0.4% | +0% | — |
| 13 |  $VOR | Vor Biopharma Inc. | $989,206 | 0.1% | +0% | — |
| 14 |  $LAB | STANDARD BIOTOOLS INC. | $256,655 | 0.0% | +0% | 34.8 |
| 15 |  $ACET | Adicet Bio, Inc. | $196,811 | 0.0% | +0% | — |
New Positions (1)
$CBRS Cerebras Systems Inc.$11.8M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for JOHNSON & JOHNSON including:
Track JOHNSON & JOHNSON's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for JOHNSON & JOHNSON and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: JOHNSON & JOHNSON
13F Pro is an AI hedge fund tracker and stock research platform. For JOHNSON & JOHNSON (SEC CIK: 200406), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in JOHNSON & JOHNSON's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.